Kura Oncology Inc (KURA)

NASDAQ
17.56
+0.08(+0.46%)
After Hours
17.56
+0.04(+0.23%)
- Real-time Data
  • Volume:
    581,429
  • Bid/Ask:
    17.25/18.18
  • Day's Range:
    17.23 - 17.81

KURA Overview

Prev. Close
17.48
Day's Range
17.23-17.81
Revenue
-
Open
17.47
52 wk Range
15.12-42.84
EPS
-1.84
Volume
581,429
Market Cap
1.16B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
549,511
P/E Ratio
-
Beta
1.63
1-Year Change
-39.45%
Shares Outstanding
66,295,508
Next Earnings Date
Mar 16, 2022
What is your sentiment on Kura Oncology Inc?
or
Market is currently closed. Voting is open during market hours.

Kura Oncology Inc News

Kura Oncology Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellSellSell
Technical IndicatorsStrong SellStrong SellBuyStrong SellStrong Sell
SummaryStrong SellStrong SellNeutralStrong SellStrong Sell

Kura Oncology Inc Company Profile

Kura Oncology Inc Company Profile

Employees
111

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.

Read More
  • What's happening guys at AH? Any good news?
    0
    • Sundial growers next week 1,5 $
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.